Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1
Inclisiran works differently from other LDL-C-lowering therapies by harnessing the intrinsic process of RNAi to increase hepatic LDL-C uptake and reduce LDL-C levels in the bloodstream.1-3
Watch the video below to learn more about the mechanism of action of inclisiran.
Multiple factors explain the sustained duration of effect of inclisiran:
Learn more about the inclisiran clinical trial data
For further information please refer to the Summary of Product Characteristics by clicking here
Inclisiran is not yet available to prescribe in the UK.
LDL-C, low-density lipoprotein cholesterol; mRNA, messenger ribonucleic acid; RISC, RNA-induced silencing complex; RNAi, ribonucleic acid interference; siRNA, small interfering ribonucleic acid.
Leqvio® Summary of Product Characteristics.
Stoekenbroek RM et al. Future Cardiol 2018;14(6):433–442.
Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.
Khvorova A. N Engl J Med 2017;376(1):4–7.
Fitzgerald K et al. N Engl J Med 2017;376(1):41–51.